

## **Assessment of spread of SARS-CoV-2 by RT-PCR and concomitant serology in children in a region heavily affected by COVID-19 pandemic**

Robert Cohen<sup>1,2,3,4,5,6</sup>, Camille Jung<sup>2,3</sup>, Naim Ouldali<sup>1,4,5,7</sup>, Aurélie Sellam<sup>1</sup>, Christophe Batard<sup>1,5</sup>, Fabienne Cahn-Sellem<sup>5</sup>, Annie Elbez<sup>1,5</sup>, Alain Wollner<sup>1</sup>, Olivier Romain<sup>1,4</sup>, François Corrad<sup>1,5</sup>, Said Abergane<sup>8</sup>, Nathalie Soismier<sup>8</sup>, Rita Creidy<sup>8</sup>, Mounira Smati-Lafarge<sup>8</sup>, Odile Launay<sup>9</sup>, Stéphane Béchet<sup>1,2</sup>, Emmanuelle Varon<sup>2,4,8</sup>, Corinne Levy<sup>1,2,3,4,5</sup>

1 ACTIV, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France

2 Université Paris Est, IMRB-GRC GEMINI, Créteil, France

3 Clinical Research Center (CRC), Centre Hospitalier Intercommunal de Créteil, Créteil, France

4 GPIP, Groupe de Pathologie Infectieuse Pédiatrique, Paris, France

5 AFPA, Association Française de Pédiatrie Ambulatoire, Saint-Germain-en-Laye, France

6 Unité Court Séjour, Petits nourrissons, Service de Néonatalogie, Centre Hospitalier Intercommunal de Créteil, France

7 Unité d'épidémiologie clinique, Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, ECEVE INSERM UMR 1123, Paris, France

8 Laboratoire de Microbiologie, Centre Hospitalier Intercommunal de Créteil, Créteil, France

9 Université Paris Descartes, Sorbonne Paris Santé, Centre d'investigation clinique Cochin-Pasteur, hôpital Cochin, Paris

**Keywords:** RT-PCR SARS-CoV-2, children, serology, spread

**Corresponding author:** Dr Corinne Levy, ACTIV, 31, rue Le Corbusier, 94000 Créteil, France. Email address: [corinne.levy@activ-france.fr](mailto:corinne.levy@activ-france.fr)  
Phone: 0033148850404

**Alternate corresponding author:** Pr Robert Cohen, ACTIV, 31, rue Le Corbusier, 94000 Créteil, France. Email address: [robert.cohen@activ-france.fr](mailto:robert.cohen@activ-france.fr)  
Phone: 0033148850404

## **Abstract**

**Background.** Several studies indicated that children seem to be less frequently infected with SARS-CoV-2 and potentially less contagious. To examine the spread of SARS-CoV-2 we combined both RT-PCR testing and serology in children in the most affected region in France, during the COVID-19 epidemic.

**Methods.** From April 14, 2020 to May 12, 2020, we conducted a cross-sectional prospective, multicenter study. Healthy controls and pauci-symptomatic children from birth to age 15 years were enrolled by 27 ambulatory pediatricians. A nasopharyngeal swab was taken for detection of SARS-CoV-2 by RT-PCR and a microsample of blood for micro-method serology.

**Results.** Among the 605 children, 322 (53.2%) were asymptomatic and 283 (46.8%) symptomatic. RT-PCR testing and serology were positive for 11 (1.8%) and 65 (10.7%) of all children, respectively. Only 3 children were RT-PCR–positive without any antibody response have been detected. The frequency of positivity on RT-PCR for SARS-CoV-2 was significantly higher in children with positive serology than those with a negative one (12.3% vs 0.6%,  $p < 0.001$ ). Contact with a person with proven COVID-19 increased the odds of positivity on RT-PCR (OR 7.8, 95% confidence interval [1.5; 40.7]) and serology (15.1 [6.6; 34.6]).

**Conclusion.** In area heavily affected by COVID-19, after the peak of the first epidemic wave and during the lockdown, the rate of children with positive SARS-CoV-2 RT-PCR was very low (1.8%), but the rate of positive on serology was higher (10.7%). Most of PCR positive children had at the same time, positive serology suggesting a low risk of transmission.

## **Introduction**

Since the beginning of the COVID-19 pandemic, reports from several countries indicated that the disease was less frequent and less severe in children than adults [1-3]. Worldwide, the number of confirmed pediatric cases seems relatively low, and they account for less than 1% of hospitalized cases and deaths [1, 4]. Although most COVID-19 cases in children are not severe, with mild clinical symptoms, serious COVID-19 illness resulting in hospitalization can occur in this age group, and recently, hyperinflammatory shock, showing features similar to atypical Kawasaki disease and Kawasaki disease shock syndrome, were reported [5].

However, concerns have been raised that children could play an important role in the spread of the disease because community testing has demonstrated a significant number of children with no or subclinical symptoms [6]. Indeed, if as for influenza, children could be the primary drivers of household SARS-CoV-2 transmission, then a silent spread from children who did not alert anyone to their infection could be a serious driver in the dynamics of the epidemic. On the basis of this prevailing hypothesis but without evidence, school closures were implemented almost ubiquitously around the world to try to halt the potential spread of COVID-19 despite early modelling suggesting that this would have less impact than most other non-pharmacological interventions [7, 8].

However, several studies had already shown that when SARS-CoV-2 infection was suspected (compatible clinical signs, contact with a person with COVID-19), the rate of positivity on RT-PCR for SARS-CoV-2 was lower in children than adults [8]. In France, during the first epidemic wave, the SARS-CoV-2-positive rate was about 2- to 7-fold less for children than adults [9]. In contrast, in RT-PCR SARS-CoV-2-positive children, the viral load was comparable between children and adults [10]. However, results from a systematic review of household clusters of COVID-19 revealed that only 3/31 clusters were due to a child index case, and a population-based school contact-tracing study found minimal

transmission by child or teacher index cases [11, 12]. Finally, other studies suggested that children were potentially less contagious than adults, with very few secondary cases involving young patients [10, 13, 14].

Some countries such as South Korea and Iceland have implemented widespread community testing. Both countries found children significantly underrepresented in cases. In Iceland, this was true in targeted testing of high-risk groups as compared with adults (6.7% < 10 years vs 13.7%  $\geq$  10 years positive), and in (invited) population screening, no child under 10 years old was positive for SARS-CoV-2 as compared with 0.8% in the general population [15].

Of note, all these studies were based on RT-PCR testing, but serology diagnosis is also an important tool to better understand the spread and burden of COVID-19 [16]. A serology survey tested adolescents in a high school in the north of France, the site of a cluster at the end of February. Of the 242 students tested, 2.7% of adolescents  $\leq$  14 years old and 40% aged 15-17 years were positive on SARS-CoV-2 serology (IgG), which suggests a difference in susceptibility among younger adolescents [17].

To best approach the spread and dynamics of transmission of SARS-CoV-2 in children at a population level, we combined both RT-PCR testing for SARS-CoV-2 and serology in asymptomatic or pauci-symptomatic children (with mild clinical symptoms) in the Paris area, the most affected region in France, during the COVID-19 epidemic.

## **Patients and Methods**

### *Study population*

This was a cross-sectional prospective, multicenter study conducted by the Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV) network, a research unit expert in epidemiological surveillance and clinical studies in ambulatory pediatric infectious

diseases, and the University Intercommunal Créteil Hospital [18]. Primary care pediatric private practices (n = 27) took part in the study from April 14, 2020 to May 12, 2020. The strategy of closing schools and the lockdown decided by the French government for the whole country started on March 17 and finished on May 11, 2020.

This study aimed to enroll children from birth to 15 years of age consulting an ambulatory pediatrician and distributed in two groups: healthy controls (asymptomatic) and pauci-symptomatic children with mild clinical symptoms. Asymptomatic children were defined as children without any symptoms or signs suggesting infectious disease. Moreover, in the asymptomatic group, we defined a subgroup of children who had symptoms (fever or respiratory or digestive) more than 7 days before enrolment. Children with symptoms were defined as those with fever isolated or associated with respiratory signs such as cough, dysphagia, rhinorrhea, diarrhea, vomiting, cutaneous signs, taste loss and/or anosmia. Children were excluded if the clinical condition at enrolment required transfer to pediatric emergency unit or hospitalization.

After informing the parents of the participating children and obtaining their signed consent, an electronic case report form (eCRF) was completed by the pediatrician to collect socio-demographic data, history, contact with a person with confirmed COVID-19, clinical symptoms and signs, and additional positive biological tests. We have also collected suspected COVID-19 contacts, because during the lockdown the diagnostic RT-PCR SARS-CoV-2 test was mainly available for patients with severe disease and/or healthcare workers, and all symptomatic individuals could not be tested. For all enrolled children, during the same visit, a nasopharyngeal (NP) swab was taken for RT-PCR detection of SARS-CoV-2 and a microsample of blood for micro-method serology.

*Calculation of the number of patients*

To have an appropriate proportion of confirmed RT-PCR SARS-CoV-2-positive patients among asymptomatic children and pauci-symptomatic patients, with a 95% confidence interval (CI) of +/-3%, assuming a positivity proportion < 10%, we needed to enroll 300 children per group (asymptomatic and pauci-symptomatic), for 600 patients in total.

### *Serological assays*

Pediatricians collected fingerstick whole-blood specimens and used the Biosynex COVID-19 BSS test, a rapid chromatographic immunoassay, for qualitative detection of IgG and IgM antibodies to SARS-CoV-2 in blood. This test is among those approved by the French national health authority [19]. According to the specifications of the manufacturer, the diagnostic accuracy of the test was sensitivity 91.8% [95% CI 83.8-96.6] and specificity 99.2% [95%CI 97.7-99.8] (<https://www.biosynex.com/laboratoires-hopitaux-tests-covid-19/>). Furthermore, assessment by independent investigators confirmed the good diagnostic accuracy of this test among hospital staff with mild disease in eastern France [20]. Positive serology was defined as a case positive for IgM and negative for IgG or positive for IgM and IgG or negative for IgM and positive for IgG. All other cases were considered to have negative serology results.

### *SARS-CoV-2 RT-PCR methods*

The NP specimens were obtained by using the collection system eSwab<sup>TM</sup> (Minitip size nylon flocked swab placed in 1 mL of modified liquid Amies transport medium, COPAN, Brescia, Italy). They were transported within 48 hours to the centralized microbiology laboratory (CHIC). Before extraction, each NP sample was inactivated by the addition of 750 µl / ml of STARMag lysis buffer solution (Seegene, South Korea). The RT-PCR for SARS-CoV-2 was performed on the automated Seegene STARlet system®, according to the manufacturer's

instructions using the CE marked Allplex™ 2019-nCoV RT-PCR assay (Seegene, South Korea®) which targets N- (viral nucleocapsid protein) and RdRP-gene (RNA-dependent RNAPolymerase), both SARS-CoV-2 specific genes, and the sarbecovirus specific E-gene (viral envelop).

In brief, the automated Hamilton STARlet system was used for automated viral RNA extraction using the STARMag 96 Universal Cartridge kit (Seegene, South Korea) and PCR set up. Subsequently, 8 µL of extracted nucleic acids was added to 17 µL of the PCR Master Mix, and amplification and detection were performed on the CFX96™ detection system (Bio-Rad, France) as per manufacturer's instruction. Ct from FAM (E gene), Cal Red 610 (RDRP gene), Quasar 670 (N gene) and HEX (internal control) were acquired. Before extraction, internal control (10 µl) was added to each reaction mix to verify extraction and determine PCR inhibition. Positive and negative controls were included in each run.

NP samples were considered positive when a cycle threshold value ( $C_t$ ) less than 40 was obtained for any gene. A sample was considered negative if the internal control was amplified but not the viral target genes. A sample was considered invalid when no amplification was obtained for the internal control.

The  $C_t$  values were used as indicators of the copy number of SARS-CoV-2 RNA in specimens with lower  $C_t$  values corresponding to higher viral copy numbers.

### *Statistical analysis*

Data were entered by using the eCRF (PHP/MySQL) and analyzed by using Stata/SE v15 (StataCorp, College Station, TX, USA). Quantitative data were compared by Student *t* test and qualitative data by chi-square or Fisher exact test. We used a logistic regression model for analysis of factors associated with positivity on RT-PCR for SARS-CoV-2 and serology. Variables (age, clinical signs, contact, siblings and daycare attendance modalities) with  $p <$

0.20 on univariate analysis were included in the model, estimating odds ratios (ORs) and 95% CIs. Only significant variables ( $p < 0.05$ ) were kept in the final model. All tests were 2-sided and were considered significant at  $p < 0.05$ .

### *Ethics*

The study protocol was approved by an ethics committee (CPP IDF IX no. 08-022). Parents of all infants provided written informed consent. The study was registered at ClinicalTrials.gov NCT04318431.

### **Results**

From April 14, 2020 to May 12, 2020, 27 ambulatory pediatricians in the Paris area enrolled 605 children: 322 (53.2%) were asymptomatic and 283 (46.8%) symptomatic. Table 1 presents the characteristics of the enrolled children by group. The mean duration from symptom onset to enrollment was  $12 \pm 15$  days (median 5) for symptomatic children. Among asymptomatic children, 118 (37%) had history of symptoms during the preceding weeks but more than 7 days before enrolment (mean  $40 \pm 22$  days; median 36). Mean age was  $4.9 \pm 3.9$  years (median 3.8) with no significant difference between the two groups. In the symptomatic group, the main signs and symptoms were fever (187, 66.3%), cough (143, 50.7%), pharyngitis (143, 50.7%), rhinitis (137, 48.4%), diarrhea (81, 28.7%), cutaneous criteria (64, 23.0%), vomiting (52, 18.8%), taste loss (8, 3.0%) and anosmia (5, 3.3%).

Figure 1 presents the dynamics of the first COVID-19 epidemic wave in France[21], the dates of the lockdown and the number of children enrolled by weeks.

RT-PCR SARS-CoV-2 tests were positive for 11 (1.8%) children, with no significant difference between the two groups (Table 2). The supplemental Table shows the details of the 11 positive RT-PCR for SARS-CoV-2. Only 5 children had positive RT-PCR SARS-CoV-2

result for all 3 amplified genes, among which only two children presented  $C_t$  between 27 and 30.

On multivariable analysis, contact with a person with COVID-19 household was the only significant risk factor for RT-PCR–positive SARS-CoV-2 infection (OR 7.8, 95% CI [1.5; 40.7]).

Table 2 shows also the serology results by group. Serology was positive for 65 (10.7%) children, whatever the group, and among these, 87.3% had a confirmed or suspected contact. The rates of confirmed or suspected contact among the positive serology cases (n=65) did not change during the study period. Table 3 presents the results of RT-PCR SARS-CoV-2 and serology in the asymptomatic group by history of symptoms and signs during the preceding weeks. Children with history of symptoms during the preceding weeks, more frequently were positive on serology.

Table 4 presents the RT-PCR SARS-CoV-2 results by serology status. The frequency of positivity on RT-PCR for SARS-CoV-2 was significantly higher in children with positive serology than those with a negative one (12.3% vs 0.6%,  $p < 0.001$ ). Only 3 children were RT-PCR SARS-CoV-2–positive without any antibody response detected.

Table 5 shows RT-PCR SARS-CoV-2 and serology positivity by contact with a person with suspected or confirmed COVID-19. Only 2 of 275 (0.7%) children without any contact with a person with COVID-19 were positive on RT-PCR for SARS-CoV-2.

On multivariate analysis, positivity on serology was associated with contact with a person with proven or suspected COVID-19 (OR 15.1 [95% CI 6.6; 34.6] and 5.8 [95% CI 2.6; 13.2]).

## **Discussion**

In the best of our knowledge, this study is the first to combine RT-PCR SARS-CoV-2 and serology results to assess the spread of SARS-CoV-2 infection in a large cohort of children in the community. In a region strongly affected by the epidemic (Paris area) but during the lockdown, very few children (1.8%) were positive on RT-PCR for SARS-CoV-2, but the rate of children positive on serology (10.7%) was higher. Despite the relatively large number of children included (>600), we did not find a significant difference in the rate of positive RT-PCR or serology results between asymptomatic and pauci-symptomatic children. This fact supports that it is unlikely the cluster screening of symptomatic children in the community will be relevant.

Among asymptomatic children, those with history of symptoms during the preceding weeks accounted for one third of children with positive serology results (13/41), which supports that asymptomatic infections are frequent in children. In contrast, history of symptoms during the preceding weeks increased significantly the risk of positive serology. However, on multivariate analysis, the only factor influencing the positivity of RT-PCR or serology was the household contact who has previously presented symptoms suggestive of COVID-19. This was noted whether this infection was proven by RT-PCR or unproven due to the absence of availability of the test. Of note, the number of siblings in the family did not significantly increase the probability of a positive RT-PCR or serology result. This finding suggests that children were usually infected by an adult in the family [11].

Without contact with a suspected or confirmed COVID-19 case, the frequency of positivity on RT-PCR for SARS-CoV-2 or serology was extremely low: 0.7% for RT-PCR and 2.9% for serology. Of the children positive on RT-PCR (n=11), only 3 had no antibody response, and 8 were positive for IgG with or without IgM positivity. This finding supports that for these 3 patients, contamination had occurred during the 2 weeks before enrollment.

We highlight that the frequency of positivity on RT-PCR for SARS-CoV-2 was significantly higher in children with positive serology than those with a negative one (12.3% vs 0.6%,  $p < 0.001$ ). This finding highlights the difficulties in interpreting the significance of a positive RT-PCR SARS-CoV-2 result without concomitant antibody testing after the epidemic wave. Indeed, children positive on RT-PCR for SARS-CoV-2 and positive for IgG probably had little or no infectivity [22]. In a study of 9 patients, attempts to isolate the virus in culture were not successful beyond day 8 of illness onset, which relates to the decreased infectivity beyond the first week [23]. In the study of Bullard *et al.*, SARS-CoV-2 Vero cell infectivity was only observed for RT-PCR  $C_t < 24$  and symptom onset to test  $< 8$  days [24]. The low infectivity is also supported in our study by the fact that only 5 children had positive RT-PCR SARS-CoV-2 result for all 3 amplified genes, among which only two children presented  $C_t$  between 27 and 30, suggesting not very high viral load.

Our study has several limitations. First, the role of assumed household transmission probably has been over-estimated because of the well-followed lockdown in France [25]. Indeed, more than 86.5% of children with positive SARS-CoV-2 by RT-PCR or serology have had a confirmed or suspected COVID-19 household contact. Second, our rate of positive serology possibly does not reflect the epidemiologic situation in the Paris area for children. Probably because COVID-19 families already affected were more likely to consult and agree to participate in the study, the population of parents of enrolled children were possibly over-represented of COVID-19-affected families as compared with the general population. Indeed, we found, 17.1% of the children included had a confirmed infected close relative and 32.3% had contact with a person household with suspected infection (without testing). Estimates of the rate of patients who were infected with SARS-Cov-2 in the Paris area was lower, close to 12% [26].

Finally, the data are consistent with the Fontanet *et al.* study, finding seropositivity in 10.2% of siblings of students in the cluster high school [17]. The importance of familial contagion in the modalities of SARS-Cov-2 transmission is underlined by a very low RT-PCR (0.7%) and serology positivity rate (3.6%) for children without an infected relative and in a period of lockdown. School closure or limitation (reduced number of students or days of attendance) has a major impact on children's development and access to learning [27]. Therefore, the usefulness of school closure or limitation needs evaluation in controlling the COVID-19 epidemic. Available data suggest that the role of children in the dynamics of the adult epidemic is probably modest, but further studies are necessary. We plan to renew this study after the re-opening of schools and day care centre in the Paris area to better assess the transmission of SARS-Cov-2 in children.

**Funding.** This work was supported by the French Ministry of Health “DGOS PHRC regional IDF 2020 no. AOR20095.”

**Disclaimer.** The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

**Potential conflicts of interest.** All other authors declare no competing interests for this study. RC, CL, EV received personal fees and non-financial support from Pfizer. RC reports personal fees from Merck, GSK, Sanofi and AstraZeneca outside the submitted work. All authors have completed the ICMJE Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**Acknowledgments.** We are grateful to the investigators of the COVILLE study Network:

Akou'ou M.H, Auvrignon A, Belaroussi N, Benani M, Cambier Nappo E, Chartier Albrech C, Coicadan L, Condor R, D'Acremont G, D'Ovidio N, De Brito B, Deberdt P, Delatour A, Gorde-Grosjean S, Louvel M, Michot-Cottias A-S, Ravilly S, Seror E, Turberg-Romain C, We are grateful to Adjemian S, Auffroy O, Begard M, Harant J, Mouaouya M, Receveau F, and Sigere ML, for technical assistance ; Cuquemelle A for secretarial assistance.

We are grateful to the ACTIV team : Ramay I, Prieur C; Prieur A, Borg M, Meyet L, Levy J, and Zemmour E (Association Clinique et thérapeutique Infantile du Val de Marne);

We are grateful to the CRC team: Brussieux M and Hoffart C from the Clinical Research Center of the CHI Créteil.

**Figure 1. Dynamics of the first COVID-19 epidemic wave in France[21], the dates of the lockdown and number of children enrolled in the study by week**

## References

1. Castagnoli R, Votto M, Licari A, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. *JAMA Pediatr* **2020**.
2. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* **2020**.
3. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. *Acta Paediatr* **2020**; 109(6): 1088-95.
4. Coronavirus Disease 2019 in Children — United States, February 12–April 2, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:422-26. doi: <http://dx.doi.org/10.15585/mmwr.mm6914e4external>. **2020**.
5. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. *Lancet* **2020**; 395(10237): 1607-8.
6. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 Among Children in China. *Pediatrics* **2020**.
7. Eubank S, Eckstrand I, Lewis B, Venkatramanan S, Marathe M, Barrett CL. Commentary on Ferguson, et al., "Impact of Non-pharmaceutical Interventions (NPIs) to Reduce COVID-19 Mortality and Healthcare Demand". *Bull Math Biol* **2020**; 82(4): 52.
8. Munro APS, Faust SN. Children are not COVID-19 super spreaders: time to go back to school. *Arch Dis Child* **2020**.
9. Levy C. Changes in RT-PCR-positive SARS-CoV-2 rates in adults and children according to the epidemic stages. <https://medrxiv.org/cgi/content/short/2020051820098863v1> **2020**.
10. Jones TC, Mühlemann B, Veith T, et al. An analysis of SARS-CoV-2 viral load by patient age. [https://zoonosencharitede/fileadmin/user\\_upload/microsites/m\\_cc05/virologie-ccm/dateien\\_upload/Weitere\\_Dateien/analysis-of-SARS-CoV-2-viral-load-by-patient-agepdf](https://zoonosencharitede/fileadmin/user_upload/microsites/m_cc05/virologie-ccm/dateien_upload/Weitere_Dateien/analysis-of-SARS-CoV-2-viral-load-by-patient-agepdf) . **2020**.


11. Zhu Y, Bloxham CJ, Hulme KD. Children are unlikely to have been the primary source of household SARS-CoV-2 infections. medRxiv preprint server 2020 doi: 10.1101/2020.03.26.20044826 [published Online First: 30 March 2020]. **2020**.
12. Zhang J, Litvinova M, Liang Y, et al. Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China. *Science* **2020**.
13. The National Institute for Public Health and the Environment (RVIM). Children and COVID-19. <https://www.rivm.nl/en/novel-coronavirus-covid-19/children-and-covid-19> [accessed 7 May 2020]. . **2020**.
14. Danis K, Epaulard O, Benet T, et al. Cluster of coronavirus disease 2019 (Covid-19) in the French Alps, 2020. *Clin Infect Dis* **2020**.
15. Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic Population. *N Engl J Med* **2020**.
16. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. *JAMA* **2020**.
17. Fontanet A, Tondeur L, Madec Y. Cluster of COVID-19 in northern France: A retrospective closed cohort study medRxiv 2020 ; published Online April 23. doi: <https://doi.org/10.1101/2020.04.18.20071134>]. **2020**.
18. Levy C, Vie le Sage F, Varon E, Chalumeau M, Grimpel E, Cohen R. Pediatric Ambulatory and Hospital Networks for Surveillance and Clinical Epidemiology of Community-Acquired Infections. *J Pediatr* **2018**; 194: 269-70 e2.
19. Evaluation of COVID-19 Tests by the French National Health Authorities. <https://covid-19.sante.gouv.fr/tests>. **2020**.
20. Fafi-Kremer S, Bruel T, Madec Y, et al. Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France. <https://www.medrxiv.org/content/101101/2020051920101832v2> **2020**.
21. Jarlier V. Number of COVID-19 cases in France <https://infogram.com/graphiques-covid-1h8n6mymkewj6xo?live>. 2020. **2020**.
22. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. *Eur J Clin Microbiol Infect Dis* **2020**; 39(6): 1059-61.
23. Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature* **2020**.
24. Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. *Clin Infect Dis* **2020**.

25. Wu J, Huang Y, Tu C, et al. Household Transmission of SARS-CoV-2, Zhuhai, China, 2020. *Clin Infect Dis* **2020**.
26. Salje H, Tran Kiem C, Lefrancq N. Estimating the burden of SARS-CoV-2 in France. *MedRxiv* 2020; <https://doi.org/10.1101/2020.04.20.20072413> **2020**.
27. <https://en.unesco.org/covid19/educationresponse/consequences>. **2020**.

■ Number of enrolled children (Coville)

— National new Covid-19 cases

Lockdown from March 17 to May 10



**Table 1. Characteristics of children enrolled in the study and by symptomatic and asymptomatic group**

	<b>Overall</b> n=605	<b>Symptomatic</b> <b>children</b> n=283	<b>Asymptomatic</b> <b>children</b> n=322	<b>p</b>
<b>Age, mean±SD (years)</b>	4.9±3.9	4.8±3.7	5.0±4.2	0.4
<b>Median</b>	3.8	4.0	3.7	
<b>&lt;3 months</b>	8 (1.3)	6 (2.1)	2 (0.6)	
<b>3-30 months</b>	218 (36.0)	98 (34.6)	120 (37.3)	
<b>31 months – 5 years</b>	184 (30.4)	96 (33.9)	88 (27.3)	0.1
<b>6 years – 10 years</b>	134 (22.2)	61 (21.6)	73 (22.7)	
<b>≥11 years</b>	61 (10.1)	22 (7.8)	39 (12.1)	
<b>Sex, male</b>	322 (53.2)	152 (53.7)	170 (52.8)	0.8
<b>Daycare attendance</b> <b>before lockdown</b>				
<b>Home</b>	78 (13.8)	34 (13.0)	44 (14.5)	
<b>Childminder</b>	55 (9.7)	24 (9.2)	31 (10.2)	0.8
<b>Daycare center</b>	135 (23.9)	66 (25.2)	69 (22.7)	
<b>School</b>	298 (52.7)	138 (52.7)	160 (52.6)	
<b>Comorbidities</b>	93 (15.4)	45 (15.9)	48 (14.9)	0.7
<b>Prematurity</b>	35 (6.3)	15 (5.7)	20 (6.9)	0.6
<b>Brothers/sisters</b>				
<b>0</b>	115 (20.6)	57 (21.9)	58 (19.4)	
<b>1</b>	282 (50.5)	136 (52.3)	146 (48.8)	0.3
<b>≥2</b>	162 (29.0)	67 (25.8)	95 (31.8)	

Data are n (%) unless indicated.

**Table 2. Results of RT-PCR SARS-Cov-2 testing and serology in children enrolled in the study and by symptomatic and asymptomatic group**

	<b>Overall</b> n=605	<b>Symptomatic</b> <b>children</b> n=283	<b>Asymptomatic</b> <b>children</b> n=322
<b>RT-PCR</b>			
<b>Overall</b>	11 (1.8) [0.9; 3.2]	7 (2.5) [1.0; 5.0]	4 (1.2) [0.3; 3.1]
<b>Definite positive</b>	5	3	2
<b>Weakly positive</b>	1	1	0
<b>Probable</b>	5	3	2
<b>Serology</b>			
<b>IgM+ and/or IgG+</b>	65 (10.7) [8.4; 13.5]	24 (8.5) [5.5; 12.4]	41 (12.7) [9.3; 16.9]
<b>IgM+IgG-</b>	7 (1.2) [0.5; 2.4]	4 (1.4) [0.4; 3.6]	3 (0.9) [0.2; 2.7]
<b>IgM+IgG+</b>	32 (5.3) [3.6; 7.4]	12 (4.2) [2.2; 7.3]	20 (6.2) [3.8; 9.4]
<b>IgM-IgG+</b>	26 (4.2) [2.8; 6.2]	8 (2.8) [1.2; 5.5]	18 (5.6) [3.3; 8.7]

Data are n (%) [95% confidence interval].

**Table 3. Results of RT-PCR SARS-Cov-2 testing and serology in asymptomatic children with and without symptoms more than 7 days before enrollment**

	<b>Overall</b> n=322	<b>With symptoms</b> n=118	<b>Without symptoms</b> n=204
<b>RT-PCR</b>			
<b>Overall</b>	4 (1.2) [0.3; 3.1]	1 (0.8) [0.0; 4.6]	3 (1.5) [0.3; 4.2]
<b>Definite positive</b>	2	0	2
<b>Weakly positive</b>	0	0	0
<b>Probable</b>	2	1	1
<b>Serology</b>			
<b>IgM+ and/or IgG+</b>	41 (12.7) [9.3; 16.9]	28 (23.7) [16.4; 32.4]*	13 (6.4) [3.4; 10.7]*
<b>IgM+IgG-</b>	3 (0.9) [0.2; 2.7]	2 (1.7) [0.2; 6.0]	1 (0.5) [0.0; 2.7]
<b>IgM+IgG+</b>	20 (6.2) [3.8; 9.4]	17 (14.4) [8.6; 22.1]*	3 (1.5) [0.3; 4.2]*
<b>IgM-IgG+</b>	18 (5.6) [3.3; 8.7]	9 (7.6) [3.5; 14.0]	9 (4.4) [2.0; 8.2]

Data are n (%) [95% confidence interval].

\* p<0.001

**Table 4. RT-PCR SARS-CoV-2–positive results by serology status**

<b>RT-PCR results</b>	IgM- IgG- n=540	IgM+ and/or IgG+ n=65	IgM+ IgG- n = 7	IgM+ IgG+ n = 32	IgM - IgG+ n = 26
Overall	3 (0.6)	8 (12.3)	0	6 (18.7)	2 (7.8)
Definite positive	2 (0.4)	3 (0.6)	0	2 (6.2)	1 (3.9)
Weakly positive	0	1 (1.5)	0	1 (3.1)	0
Probable	1 (0.2)	4 (6.2)	0	3 (9.4)	1 (3.9)

Data are n (%).

-  $p < 0.001$ : comparison of overall RT-PCR with IgM-/IgG- vs IgM+ and/or IgG+

-  $p < 0.001$ : comparison of definite or weakly or probable RT-PCR with IgM-/IgG- vs IgM+ and/or IgG+

**Table 5. RT-PCR and serology results by contact with a person with confirmed and/or suspected COVID-19**

<b>Contact</b>	<b>Overall n=543*</b>	<b>Positive serology n=63</b>	<b>Negative serology n=480</b>	<b>Positive RT-PCR SARS-CoV-2 n=11</b>	<b>Negative RT-PCR SARS- CoV-2 n=532</b>
Confirmed COVID-19	93 (17.1) [14.1; 20.6]	29 (31.2) [22.0; 41.6]	64 (68.8) [58.4; 78.0]	5 (5.4) [1.8; 12.1]	88 (94.6) [87.9; 98.2]
Suspected COVID-19	175 (32.2) [28.3; 36.3]	26 (14.9) [9.9; 21.0]	149 (85.1) [79.0; 90.0]	4 (2.3) [0.6; 5.7]	171 (97.7) [94.3; 99.4]
Confirmed/ suspected COVID-19	268 (49.4) [45.1; 53.6]	55 (20.5) [15.9; 25.9]	213 (79.5) [74.1; 84.1]	9 (3.4) [1.5; 6.3]	259 (96.6) [93.7; 98.5]
No contact	275 (50.6) [46.4; 54.9]	8 (2.9) [1.3; 5.7]	267 (97.1) [94.3; 98.7]	2 (0.7) [0.1; 2.6]	273 (99.3) [97.4; 99.9]

Data are n (%) [95% confidence interval].

\* 543 available data on 605 enrolled patients

**Supplemental table. Description of the 11 patients with positive RT-PCR for SARS-CoV-2**

<b>Patients</b>	<b>Target</b>	<b>Result</b>	<b>Ct</b>
Patient 1 (9.4 years)	E gene	-	NA
	RdRP gene	-	NA
	N gene	+	38.45
	IC	+	25.52
Patient 2 (5.1 years)	rs	-	NA
	RdRP gene	-	NA
	N gene	+	34.85
	IC	+	25.04
Patient 3 (4.5 years)	E gene	-	NA
	RdRP gene	-	NA
	N gene	+	36.38
	IC	+	26.04
Patient 4 (5.6 years)	E gene	+	30.91
	RdRP gene	+	32.75
	N gene	+	32.83
	IC	+	26.05
Patient 5 (19 days)	E gene	+	27.20
	RdRP gene	+	28.66
	N gene	+	28.59
	IC	+	25.20
Patient 6 (2.1 years)	E gene	-	NA
	RdRP gene	+	38.91
	N gene	+	38.84
	IC	+	25.91
Patient 7 (4.8 years)	E gene	-	NA
	RdRP gene	+	34.60
	N gene	+	37.52
	IC	+	25.62
Patient 8 (9.5 years)	E gene	-	NA
	RdRP gene	-	NA
	N gene	+	38.63
	IC	+	25.97
Patient 9 (1.8 years)	E gene	-	NA
	RdRP gene	+	35.26
	N gene	+	35.51
	IC	+	25.95
Patient 10 (6.5 years)	E gene	-	NA
	RdRP gene	+	37.59
	N gene	-	NA
	IC	+	25.21

Patient 11 (9.3 years)	E gene	+	28.00
	RdRP gene	+	29.41
	N gene	+	30.14
	IC	+	25.69

Ct, Cycle threshold, IC, internal control, NA, not applicable